Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Indivior PLC Ordinary Shares(INDV)
Top performer 
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for INDV
11/05/2026: INDV (4-star) is currently NOT-A-BUY. Pass it for now.
Indivior is a specialty pharmaceutical company focused on developing treatments for substance use and mental health disorders. Its primary strength lies in its portfolio of long-acting injectable medicines, such as Sublocade, which have established a leading position in the opioid use disorder market. The investment story centers on the company’s ability to pivot toward high-growth, proprietary treatments while navigating legacy regulatory challenges. However, investors must consider risks related to intense generic competition, heavy US market concentration, and potential ongoing legal exposures. Indivior may suit growth-oriented investors interested in healthcare innovation, provided they are prepared for the volatility associated with its evolving business model and regulatory landscape.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers growth potential through product adoption but carries substantial execution and regulatory risk. |
| Momentum investor | Weak fit | Momentum is often hampered by sector-specific regulatory noise and litigation history. |
| Value investor | Mixed fit | Valuation may appear attractive depending on long-term growth success, but quality-of-earnings risks remain. |
| Dividend investor | Weak fit | Indivior does not currently focus on providing significant income to shareholders. |
| Low-risk investor | Weak fit | Significant regulatory and litigation risks make this a high-volatility, higher-risk investment. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock price is sensitive to clinical trial results, regulatory rulings, and litigation updates. |
| Valuation risk | Medium | Future growth expectations are highly dependent on the continued market adoption of Sublocade. |
| Competition risk (Generic and Specialty) | High | The entry of generic competitors and new therapies poses a constant threat to market share. |
| Business quality | Medium | The company has strong products but faces operational challenges inherent in the specialty pharma business model. |
| Dividend income | Low / none | Investors should not rely on this stock for consistent dividend income. |
| Execution risk | Medium / high | Successfully managing a product transition while facing legal headwinds requires precise execution. |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.28B USD | Price to earnings Ratio 10.16 | 1Y Target Price 49.5 |
Price to earnings Ratio 10.16 | 1Y Target Price 49.5 | ||
Volume (30-day avg) 3.1M shares | Beta 1.13 | 52 Weeks Range 21.48 - 37.01 | Updated Date 11/12/2026 |
52 Weeks Range 21.48 - 37.01 | Updated Date 11/12/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.57 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Drug Manufacturers - Specialty & Generic
- BUY participation
- 66.7%
- Active BUY / eligible
- 8 / 12
- 30-Day BUY Count Change
- +3
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 141.07% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/05/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Opioid Use Disorder Treatments | Includes Sublocade and other buprenorphine-based products. | The majority of revenue comes from helping patients manage opioid dependency. |
| Mental Health / Other | Includes Perseris and newer pipeline assets. | These represent the company's efforts to diversify into broader mental health conditions. |
| Geography | Primary operations in the United States with some international exposure. | The company is heavily dependent on the US healthcare system and regulatory environment. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-10-29 | When Before Market | Estimate 0.93 | Actual 1.32 |
Profitability
Profit Margin 32.75% | Operating Margin (TTM) 54.78% |
Management Effectiveness
Return on Assets (TTM) 29.34% | Return on Equity (TTM) 12.2% |
Valuation
Trailing PE 10.16 | Forward PE 9.4 | Enterprise Value 4.48B | Price to Sales(TTM) 3.12 |
Enterprise Value 4.48B | Price to Sales(TTM) 3.12 | ||
Enterprise Value to Revenue 3.26 | Enterprise Value to EBITDA 7.88 | Shares Outstanding 118.04M | Shares Floating 109.48M |
Shares Outstanding 118.04M | Shares Floating 109.48M | ||
Percent Insiders 1.02 | Percent Institutions 59.66 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.